Vistagen Tackles Mental Fatigue with Investigational Nasal Spray
Biopharmaceutical company, Vistagen (Nasdaq: VTGN), is tackling mental fatigue with PH15, an investigational pherine nasal spray. The company has reported positive results from a Phase 2a pilot study of PH15, which has demonstrated statistically significant improvement of psychomotor impairment caused by mental fatigue. Vistagen’s study compared PH15 to placebo and caffeine in sleep-deprived study participants and found that PH15 was well-tolerated with no serious adverse events reported.
The company’s share price settled down 0.42% in intraday trading following the news on Thursday, before rising 2.55% aftermarket.
“These pilot findings contribute to our confidence in PH15’s potential as an innovative treatment for enhancing psychomotor performance and potentially cognitive impairment, particularly in addressing the challenges of mental fatigue,” said Shawn Singh, Chief Executive Officer of Vistagen.
“Numerous disorders, such as shift work disorder, sleep apnea, and narcolepsy, can lead to debilitating sleep deprivation and mental fatigue. Individuals affected by these disorders require improved treatment options with a differentiated safety profile, one without the potential for abuse liability or negative and treatment-limiting side effects and safety concerns. We anticipate exploring PH15’s potential to emerge as a new and transformative solution for these underserved individuals.”
PH15 is an odorless, tasteless synthetic investigational pherine with a novel, rapid-onset proposed mechanism of action (MOA) that is fundamentally differentiated from the MOA of all currently approved treatments to improve psychomotor or cognitive impairment caused by mental fatigue.
Vistagen is currently evaluating the potential Phase 2 development path forward for PH15 and a nonclinical program required to support an Investigational New Drug (IND) application to facilitate further Phase 2 development of PH15 in the U.S.
About Vistagen
Vistagen (Nasdaq: VTGN) is a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. Five of Vistagen’s clinical-stage neuroscience pipeline candidates belong to a new class of drugs known as pherines, which are investigational neuroactive nasal sprays with innovative proposed mechanisms of action that activate chemosensory neurons in the nasal passages to impact fundamental neural circuitry in the brain without the need for systemic absorption or binding to receptors in the brain. Vistagen’s sixth investigational candidate is an oral prodrug with potential to modulate NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders. Connect at www.Vistagen.com.
